Hospital Universitario de la Princesa -ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596

2021

  1. Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy

    Journal of Viral Hepatitis, Vol. 28, Núm. 6, pp. 878-886

  2. Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response

    AIDS (London, England), Vol. 35, Núm. 13, pp. 2119-2127

  3. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 5, pp. e96-e102

  4. Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 9, pp. 2375-2379

2020

  1. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients

    AIDS (London, England), Vol. 34, Núm. 10, pp. 1497-1507

  2. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362

2019

  1. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 48-54

  2. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks

    Journal of Infection, Vol. 79, Núm. 1, pp. 30-35

  3. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

    AIDS, Vol. 33, Núm. 2, pp. 269-278

2018

  1. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

    HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30

2017

  1. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

    HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134

2016

  1. Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884

  2. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1

2013

  1. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis

    Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653

  2. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

2012

  1. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

    AIDS, Vol. 26, Núm. 13, pp. 1721-1724

  2. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis

    Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726